Literature DB >> 18156932

Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients.

Myrddin Rees1, Paris P Tekkis, Fenella K S Welsh, Thomas O'Rourke, Timothy G John.   

Abstract

OBJECTIVE: To identify risk factors associated with cancer-specific survival and develop a predictive model for patients undergoing primary hepatic resection for metastatic colorectal cancer.
BACKGROUND: No published studies investigated collectively the inter-relation of factors related to patient cancer-specific survival after hepatectomy for metastatic colorectal cancer.
METHODS: Clinical, pathologic, and complete follow-up data were prospectively collected from 929 consecutive patients undergoing primary (n = 925) or repeat hepatic resection (n = 80) for colorectal liver metastases at a tertiary referral center from 1987 to 2005. Parametric survival analysis was used to identify predictors of cancer-specific survival and develop a predictive model. The model was validated using measures of discrimination and calibration.
RESULTS: Postoperative mortality and morbidity were 1.5% and 25.9%, respectively. 5-year and 10-year cancer-specific survival were 36% and 23%. On multivariate analysis, 7 risk factors were found to be independent predictors of poor survival: number of hepatic metastases >3, node positive primary, poorly differentiated primary, extrahepatic disease, tumor diameter > or =5 cm, carcinoembryonic antigen level >60 ng/mL, and positive resection margin. The first 6 of these criteria were used in a preoperative scoring system and the last 6 in the postoperative setting. Patients with the worst postoperative prognostic criteria had an expected median cancer-specific survival of 0.7 years and a 5-year cancer-specific survival of 2%. Conversely, patients with the best prognostic postoperative criteria had an expected median cancer-specific survival of 7.4 years and a 5-year cancer-specific survival of 64%. When tested both predictive models fitted the data well with no significant differences between observed and predicted outcomes (P > 0.05).
CONCLUSION: Resection of liver metastases provides good long-term cancer-specific survival benefit, which can be quantified pre- or postoperatively using the criteria described. The "Basingstoke Predictive Index" may be used for risk-stratifying patients who may benefit from intensive surveillance and selection for adjuvant therapy and trials.

Entities:  

Mesh:

Year:  2008        PMID: 18156932     DOI: 10.1097/SLA.0b013e31815aa2c2

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  354 in total

Review 1.  The surgical treatment of patients with colorectal cancer and liver metastases in the setting of the "liver first" approach.

Authors:  Leonardo Patrlj; Mario Kopljar; Robert Kliček; Masa Hrelec Patrlj; Marijan Kolovrat; Mislav Rakić; Antonija Duzel
Journal:  Hepatobiliary Surg Nutr       Date:  2014-10       Impact factor: 7.293

2.  Survival after lung metastasectomy in colorectal cancer patients with previously resected liver metastases.

Authors:  Michel Gonzalez; John Henri Robert; Nermin Halkic; Gilles Mentha; Arnaud Roth; Thomas Perneger; Hans Beat Ris; Pascal Gervaz
Journal:  World J Surg       Date:  2012-02       Impact factor: 3.352

3.  The role of 18FDG PET/CT in the management of colorectal liver metastases.

Authors:  Alec H Engledow; James R A Skipworth; Farrokh Pakzad; Charles Imber; Peter J Ell; Ashley M Groves
Journal:  HPB (Oxford)       Date:  2011-11-14       Impact factor: 3.647

4.  Laparoscopic and open liver resection for colorectal metastases: different indications?

Authors:  Airazat M Kazaryan; Bård I Røsok; Bjørn Edwin
Journal:  HPB (Oxford)       Date:  2010-08       Impact factor: 3.647

5.  Safety analysis of the oncological outcome after vein-preserving surgery for colorectal liver metastases detached from the main hepatic veins.

Authors:  Federico Tomassini; Italo Bonadio; Peter Smeets; Karen De Paepe; Giammauro Berardi; Liesbeth Ferdinande; Stéphanie Laurent; Louis J Libbrecht; Karen Geboes; Roberto I Troisi
Journal:  Langenbecks Arch Surg       Date:  2015-08-12       Impact factor: 3.445

6.  Is there a survival benefit to neoadjuvant versus adjuvant chemotherapy, combined with surgery for resectable colorectal liver metastases?

Authors:  Nir Lubezky; Ravit Geva; Einat Shmueli; Richard Nakache; Joseph M Klausner; Arie Figer; Menahem Ben-Haim
Journal:  World J Surg       Date:  2009-05       Impact factor: 3.352

7.  Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway.

Authors:  Po-Chen Chu; Peng-Chan Lin; Hsing-Yu Wu; Kuen-Tyng Lin; Christina Wu; Tanios Bekaii-Saab; Yih-Jyh Lin; Chung-Ta Lee; Jeng-Chang Lee; Ching-Shih Chen
Journal:  Oncogene       Date:  2018-03-21       Impact factor: 9.867

8.  Computed Tomography Image Texture: A Noninvasive Prognostic Marker of Hepatic Recurrence After Hepatectomy for Metastatic Colorectal Cancer.

Authors:  Amber L Simpson; Alexandre Doussot; John M Creasy; Lauryn B Adams; Peter J Allen; Ronald P DeMatteo; Mithat Gönen; Nancy E Kemeny; T Peter Kingham; Jinru Shia; William R Jarnagin; Richard K G Do; Michael I D'Angelica
Journal:  Ann Surg Oncol       Date:  2017-05-30       Impact factor: 5.344

9.  mRNA expression profiles of colorectal liver metastases as a novel biomarker for early recurrence after partial hepatectomy.

Authors:  E P van der Stok; M Smid; A M Sieuwerts; P B Vermeulen; S Sleijfer; N Ayez; D J Grünhagen; J W M Martens; C Verhoef
Journal:  Mol Oncol       Date:  2016-09-20       Impact factor: 6.603

10.  Safety and outcomes following resection of colorectal liver metastases in the era of current perioperative chemotherapy.

Authors:  Ilia Gur; Brian S Diggs; Jesse A Wagner; Gina M Vaccaro; Charles D Lopez; Brett C Sheppard; Susan L Orloff; Kevin G Billingsley
Journal:  J Gastrointest Surg       Date:  2013-10-04       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.